Nanomedicine with Neuroprotective Activity

Dear Colleagues,

Neurodegenerative disease is a type of neurological disorder that alters brain functionality due to the progressive deterioration of neurons in different brain regions. A wide range of diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis, Huntington’s disease, amyotrophic lateral sclerosis, etc., are neurodegenerative diseases. The most common neurodegenerative diseases are AD and PD. Aging populations are the main target for these diseases as older people experience cognitive impairments, decrease in muscle control and motor coordination, impaired language, memory loss, and a reduction in quality of life. As stated by the World Health Organization, neurodegenerative disease will be the biggest health issue of the twenty-first century. Due to years of extensive research, we understand the cause of neuronal loss in these types of diseases, such as genetic predisposition, proteins and plaque deposition, tangle formation, protein misfolding auto-immune attack, neuroinflammation, mitochondrial dysfunction, dysregulated autophagy, apoptosis, oxidative stress, etc. However, there is no specific treatment to cure these diseases; rather, it is the symptoms which are treated. One of the biggest obstacles to treating these diseases effectively is the blood–brain barrier, blood–cerebrospinal fluid, and P-glycoproteins. Conventional drug delivery methods cannot cross these barriers at a lower dosage, whereas a higher dosage can cause severe adverse neurotoxicity. Nanoparticles can serve as a drug carrier across these barriers to receive the therapeutic effects of these drugs. Nanoparticle-based drug delivery systems not only amplify drugs’ therapeutic effects but also mitigate toxicity that can be caused due to overdosage. This Special Issue intends to publish papers which focus on the recent advances in nanotechnology or nanoparticle-based drug delivery systems involved in treating neurodegenerative diseases in preclinical settings.

Dr. Venkatesan Perumal
Dr. Arun Reddy Ravula
Dr. Agnieszka Agas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• nanotechnology
• drug delivery
• CNS diseases
• neurodegenerative disorders
• Alzheimer’s disease
• Parkinson’s disease
• Huntington’s disease
• cognitive impairments
• memory loss
• progressive neurodegeneration